Movement Disorders最新文献

{"title":"Movement Disorders: Volume 40, Number 7, July 2025","authors":"","doi":"10.1002/mds.30305","DOIUrl":"https://doi.org/10.1002/mds.30305","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"40 7","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.30305","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144647154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards Adaptive Deep Brain Stimulation for Non-Motor Symptoms in Parkinson's Disease?","authors":"Bart E K S Swinnen,Colin W Hoy,Simon J Little","doi":"10.1002/mds.30212","DOIUrl":"https://doi.org/10.1002/mds.30212","url":null,"abstract":"Non-motor symptoms are prevalent, disabling, and difficult to treat at all stages of Parkinson's disease (PD). Whereas current deep brain stimulation (DBS) for PD targets motor symptoms, quality of life improvement, or lack thereof, is often largely determined by non-motor symptoms. So far, the effect of DBS on non-motor PD symptoms is insufficient, and neuromodulation targeted specifically at improving non-motor PD symptoms has been largely unaddressed. In this review, we provide a comprehensive overview of the effect of DBS on non-motor PD symptoms and discuss DBS-induced non-motor side effects including apathy and hypomania. We highlight the distinct neuroanatomical and temporal dynamics of these non-motor PD aspects. With the recent emergence of sensing-enabled DBS devices, we propose that research into responsive neuromodulation targeted specifically at non-motor symptoms is now feasible and timely. We outline potential non-motor adaptive DBS (aDBS) strategies that could be tested with currently available hardware. We conclude by highlighting important challenges that would need to be addressed for implementing aDBS for non-motor symptoms in PD. These include physiomarker validation, optimization of aDBS algorithms and control policies, the need for technological innovations, and incorporating ethical considerations. This review aims to provide a roadmap for clinicians and researchers to accelerate the development of non-motor aDBS in PD. © 2025 International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"121 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144652890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attention/Working Memory and Executive Function in Parkinson's Disease: Review, Critique, and Recommendations.","authors":"Roberta Biundo,Ondrej Bezdicek,Davide Maria Cammisuli,Brenna Cholerton,John C Dalrymple-Alford,Nicola Edelstyn,Eleonora Fiorenzato,Erin Holker,Saul Martinez-Horta,Alice Martini,Gabriella Santangelo,Barbara Segura,Chiara Siri,Alexander Tröster,Tiago A Mestre,Álvaro Sánchez Ferro,Michelle Hyczy de Siqueira Tosin,Matej Skorvanek,Daniel Weintraub,Gert J Geurtsen, ","doi":"10.1002/mds.30293","DOIUrl":"https://doi.org/10.1002/mds.30293","url":null,"abstract":"BACKGROUNDCognitive impairment in Parkinson's disease (PD) is a well-established non-motor complication that significantly affects the quality of life and well-being of both patients and care partners. To optimally detect mild cognitive impairment or dementia, extensive neuropsychological assessment is essential. A wide range of cognitive tests and clinical outcome assessments have been used in clinical settings, often without regard to their clinimetric quality.METHODSWe performed a literature review of tests assessing attention/working memory and executive domains in PD (tests on other domains are included in an accompanying review). The selected tests were evaluated for their clinimetric properties and categorized by a panel of experts as \"recommended,\" \"recommended with caveats,\" \"suggested,\" or \"listed\" according to the International Parkinson and Movement Disorder Society Clinical Outcome Assessment Scientific Evaluation Committee guidelines.RESULTSA total of 30 tests were reviewed. Eight tests were \"recommended,\" including four tests assessing attention/working memory abilities (WAIS-IV Digit Span, Coding and Symbol Search subtests, and Trail Making Test) and four tests assessing executive abilities (WAIS-IV Similarities, Wisconsin Card Sorting Test, Fluency Tests, and Stroop Color-Word Test). These tests demonstrated good to excellent levels of reliability and validity, have normative datasets, and are sensitive to change. Eight other tests were \"recommended with caveats\", eleven were \"suggested,\" and three were \"listed.\"CONCLUSIONSThe recommended tests for attention/working memory and executive functioning in PD can guide PD cognitive assessment. Other tests were identified as potentially useful; however, caution is advised due to their clinimetric limitations. Further validation studies are required for these tests. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"48 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144652802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subacute Painful Axonal Polyneuropathy Associated with Foslevodopa/Foscarbidopa Subcutaneous Infusion in Advanced Parkinson's Disease.","authors":"Aukusti Valli,Filip Scheperjans","doi":"10.1002/mds.30297","DOIUrl":"https://doi.org/10.1002/mds.30297","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"109 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144652841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The FDA Has Ended Required Blood Monitoring for Clozapine Use-Will This Impact the Management of Parkinson's Disease Psychosis?","authors":"Daniel Weintraub,Izabelle Schoen","doi":"10.1002/mds.30295","DOIUrl":"https://doi.org/10.1002/mds.30295","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"12 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144630353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering the Janus-Faced Nature of the Apolipoprotein Superfamily in Parkinsonian Neurodegeneration: Molecular Crosstalk Between the Astroglial Secretome and Neuronal Homeostasis.","authors":"Yingying Dai,Mingxia Bi,Qian Jiao,Xixun Du,Xi Chen,Chunling Yan,Hong Jiang","doi":"10.1002/mds.30294","DOIUrl":"https://doi.org/10.1002/mds.30294","url":null,"abstract":"Astrocytes communicate bidirectionally with neurons. The concerted activity of the neuron-astrocyte system is responsible for the progressive destruction of dopaminergic neurons in Parkinson's disease (PD). There is an urgent need to explore new prevention and treatment strategies for PD because of the lack of effective pharmaceutical therapies. Studies have shown that high levels of the apolipoprotein superfamily proteins apolipoprotein A1, apolipoprotein E, apolipoprotein D, and apolipoprotein J significantly affect susceptibility to PD. Astrocytes are the principal cells of the central nervous system and are responsible for producing these apolipoproteins. An overview of the progress in research on the effects of these astrocytic apolipoproteins on PD, especially their role in pathological processes such as lipid metabolism, α-synuclein aggregation, transcellular propagation, ferroptosis, antioxidant effects, and antiapoptotic effects, is presented. Furthermore, abnormally activated astrocytes may affect the endocytosis and secretion of apolipoprotein superfamily proteins in PD. We highlight the importance of developing novel treatments for PD from a precision medicine perspective based on the roles of apolipoprotein superfamily members within the astrocyte-neuron system. © 2025 International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"23 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144622149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Digital Frontier in Huntington's Disease: Opportunities for Clinical Trials.","authors":"Lori Quinn,Matthew W Roché,Jonas Dorn,Jamie L Adams","doi":"10.1002/mds.30277","DOIUrl":"https://doi.org/10.1002/mds.30277","url":null,"abstract":"The emergence of genetic and disease-modifying interventions in Huntington's disease (HD) necessitates early and accurate assessment of disease progression. Current end points, such as the Unified Huntington's Disease Rating Scale's Total Functional Capacity Scale and Total Motor Score, are insufficiently sensitive to detect subtle changes in early HD. Digital measures offer a promising solution by providing objective and sensitive assessments of a spectrum of impairments in early HD. Despite their potential, formal validation studies are lacking. The HD Integrated Staging System aims to standardize clinical research, but digital measures have yet to be evaluated within this framework. This review examines the current state of digital measures in HD and proposes a roadmap for future research. Current studies in neurodegenerative diseases and specifically in HD show promise for digital measures in early-stage clinical trials, but more research is needed to assess longitudinal performance and sensitivity to disease progression. Digital health technologies, including portable and wearable devices, can provide continuous data reflecting real-life performance. Measurements derived from these devices have the potential to serve monitoring and response biomarker roles in HD clinical research, aiding early decision-making in trials. This review underscores the need for validation and regulatory considerations for digital measures as clinical trial end points and also the importance of understanding the relationship between digital measures and meaningful aspects of health, particularly before clinical motor diagnosis. Future research should focus on establishing digital measures as sensitive and clinically meaningful end points for early HD, integrating them with patient-reported outcomes to inform therapeutic development. © 2025 International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"5 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144622148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematopoietic Stem Cell Transplantation in an International Cohort of Colony Stimulating Factor-1 Receptor (CSF1R)-Related Disorder.","authors":"Hemmo A F Yska,Marianne Golse,Shanice Beerepoot,Stefanie Hayer,Caroline Bergner,Anderson Rodrigues Brandao de Paiva,Cecilia Marelli,Natalia Julia Palacios,Yudy Llamas Osorio,Camille Huiban,Georg Franke,Friederike Wortmann,Udo Holtick,Xavier Ayrignac,Marjo S van der Knaap,Ludger Schöls,Vincent Perlbarg,Damien Galanaud,Moniek A de Witte,Nicole I Wolf,Stéphanie Nguyen,Fanny Mochel, ","doi":"10.1002/mds.30282","DOIUrl":"https://doi.org/10.1002/mds.30282","url":null,"abstract":"BACKGROUNDColony stimulating factor-1 receptor (CSF1R)-related disorder (CSF1R-RD) is an autosomal dominant, rapidly progressive, demyelinating disease leading to death usually within a few years. Because of the central role of CSF1R in microglia functions, allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested as a therapy for CSF1R-RD.OBJECTIVESTo report multicenter clinical (Expanded Disability Scoring Scale [EDSS]), neurocognitive), neuroimaging (Sundal score), and biological (neurofilament light chain [NfL]) outcomes after HSCT in CSF1R-RD.METHODSWe report an international cohort of 17 adult patients (8 females/9 males, 43.3 ± 9.4 years) who were treated in seven transplant centers. Patients were evaluated for a median of 2.5 years post-HSCT, including one patient with follow-up of 8 years. We also report neurological outcomes of the first child transplanted to date with biallelic CSF1R variants.RESULTSIn the first 6 months post-HSCT, 2 patients died from early complications of myeloablative transplantation, and clinical and radiological severity scores worsened in most surviving adult patients. At 12 months post-HSCT, most patients completely stabilized or improved in certain clinical domains. Radiological scores fully stabilized or slightly improved in all but one of the patients. Plasma/serum NfL sharply decreased in most patients after transplantation. Notably, 7/8 adult patients who received a reduced-intensity conditioning regimen displayed similar neurological outcomes as patients who underwent myeloablative transplantation.CONCLUSIONSAfter an initial clinical and radiological deterioration in the first 6 months post-transplantation, HSCT can halt disease progression in patients with CSF1R-RD, regardless of their presenting clinical symptoms. The possibility of reduced conditioning regimens in CSF1R-RD opens the way to treat older patients. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"36 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144612885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Levels of Extracellular Vesicle‐Associated TAOK1 in Plasma: A Diagnostic Marker for Cognitive Decline in Parkinson's Disease Dementia and Alzheimer's Disease","authors":"Pin‐Jui Kung, Yi‐Tzang Tsai, Rwei‐Ling Yu, Hsiang‐Hsuan Lin‐Wang, Ming‐Che Kuo, Chia‐Ching Wu, Chien‐Tai Hong, Koji Ueda, Shau‐Ping Lin, Ruey‐Meei Wu","doi":"10.1002/mds.30287","DOIUrl":"https://doi.org/10.1002/mds.30287","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"4 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease-Modifying Trials in Treated Parkinson's Disease: \"Stable Treated\" Does Not Equate with Biological Stability.","authors":"M Maral Mouradian,A Jon Stoessl,Anthony E Lang","doi":"10.1002/mds.30259","DOIUrl":"https://doi.org/10.1002/mds.30259","url":null,"abstract":"Traditionally, clinical trials of putative disease-modifying therapies in Parkinson's disease have enrolled untreated patients at the earliest clinical stages of their disease. Due to a number of challenges inherent with this approach, there has been a recent move to a different study design, enrolling patients who are already taking \"stable\" anti-parkinson medication. However, typically, the symptomatic treatment regimen has not been defined uniformly with respect to drugs and dosages utilized or duration of therapy. More importantly, this approach fails to consider or account for the major pharmacodynamic changes induced in the parkinsonian brain by varying dopaminergic therapies (particularly levodopa) and the impact of these on both clinical and neuroimaging outcome measures. In this review, we highlight what is known about the changes induced by dopaminergic therapy and the challenges these will present in the interpretation of outcomes of studies using this trial design. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"21 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144594101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}